Squaric acid derivatives as inhibitors of the nicotinamide
The present application discloses novel squaric acid derivatives of the formula A: from —C(═O)—, —S(═O) 2 —, —C(═S)— and —P(═O)(R 5 )—; B: -, —O—, —NR 6 — and —C(═O)—NR 6 —; D: -, —O—, —CR 7 R 8 — and —NR 9 ; m=0-12; n=0-12; m+n=1-20; p=0-2; R 1 : heteroaryl, aryl; R 2 : H, C 1-12 -alkyl, C 3-12 -cycloalkyl, —[CH 2 CH 2 O] 1-10 —(C 1-6 -alkyl), C 1-12 -alkenyl, aryl, heterocyclyl, heteroaryl; R 3 : C 1-12 -alkyl, C 3-12 -cycloalkyl, —[CH 2 CH 2 O] 1-10 —(C 1-6 -alkyl), C 1-12 -alkenyl, aryl, heterocyclyl, heteroaryl; or R 2 and R 3 : N-containing heterocyclic/heteroaromatic ring; R 4 and R 4 *: H, C 1-12 -alkyl, C 1-12 -alkenyl; and pharmaceutically acceptable salts and prodrugs thereof, and their use in the treatment of diseases/conditions caused by an elevated level of NAMPRT (inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease, asthma and CPOD, osteoarthritis, osteoporosis and fibrotic diseases; dermatosis; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, cachexia, inflammation associated with infection and viral infections, adult respiratory distress syndrome, ataxia telengiectasia).
1. A compound of the formula (I)
wherein
A is selected from —C(═O)—, —S(═O) 2 —, —C(═S)— and —P(═O)(R 5 )—, wherein R 5 is selected from C 1-6 -alkyl, C 1-6 -alkoxy, and hydroxy;
B is selected from a single bond, —O—, —NR 6 — and —C(═O)—NR 6 —, wherein R 6 is selected from hydrogen, optionally substituted C 1-12 -alkyl, optionally substituted C 1-12 -alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl;
D is selected from a single bond, —O—, —CR 7 R 8 — and —NR 9 , wherein R 7 , R 8 and R 9 are independently selected from hydrogen, optionally substituted, alkyl, optionally substituted C 1-12 -alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl;
m in is an integer of 0-12 and n is an integer of 0-12, wherein the sum m+n is 1-20;
p is an integer of 0-2
R 1 is optionally substituted pyridinyl;
R 2 is selected from hydrogen, optionally substituted C 1-12 -alkyl, optionally substituted C 3-12 -cycloalkyl, —[CH 2 CH 2 O] 1-10 -(optionally substituted C 1-6 -alkyl), optionally substituted C 1-12 -alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; and R 3 is selected from optionally substituted C 1-12 -alkyl, optionally substituted C 3-12 -cycloalkyl, —[CH 2 CH 2 O] 1-10 -(optionally substituted C 1-6 -alkyl), optionally substituted C 1-12 -alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or R 2 and R 3 together with the intervening atoms form an optionally substituted N-containing heterocyclic or heteroaromatic ring;
each of R 4 and R 4 * is independently selected from hydrogen, optionally substituted C 1-12 -alkyl and optionally substituted C 1-12 -alkenyl;
and pharmaceutically acceptable salts thereof, and prodrugs thereof.
2. The compound according to claim 1 , wherein B is selected from —O— and —NR 5 .
3. The compound according to claim 2 , wherein A is —S(═O) 2 — and B is —O—.
4. The compound according to claim 2 , wherein A is —C(═O)— and B is —O—.
5. The compound according to claim 2 , wherein D is a single bond.
6. The compound according to claim 1 , wherein B is a single bond.
7. The compound according to claim 6 , wherein A is —S(═O) 2 —.
8. The compound according to claim 1 , wherein B is —C(═O)—NR 5 —.
9. The compound according to claim 1 , wherein D is selected from a single bond, —O—, and —NR 9 .
10. The compound according to claim 1 , wherein p is 0 and R 1 is pyridine-4-yl.
11. The compound according to claim 1 , Wherein m is an integer of 0-10 and n is an integer of 0-10, wherein the sum m+n is 1-12.
12. The compound according to claim 11 , wherein m is an integer of 2-8 and n is 0.
13. The compound according to claim 1 , wherein R 2 and R 3 together with the intervening atoms form an optionally substituted N,O-containing heterocyclic or heteroaromatic ring.
14. The compound according to claim 1 , wherein R 4 is selected from hydrogen, C 1-6 -alkyl and optionally substituted benzyl; and R 4 * is hydrogen.
15. The compound according to claim 1 , wherein
A is selected from —C(═O)— and —S(═O) 2 —;
B is —O—;
D is selected from a single bond, —O—, and —NR 9 ,
m is an integer of 2-8 and n is 0;
R 2 is selected from hydrogen, optionally substituted C 3-12 -cycloalkyl, —[CH 2 CH 2 O] 1-10 -(optionally substituted Ci- 6 -alkyl), —(CH 2 ) 0-2 -(optionally substituted aryl), —(CH 2 ) 0-2 -substituted heteroaryl) and —(CH 2 ) 0-2 -(optionally substituted heterocyclyl);
R 3 is selected from optionally substituted C 3-12 -cycloalkyl, —[CH 2 CH 2 O] 1-10 -(optionally substituted C 1-6 -alkyl), optionally substituted C 1-12 -alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl;
R 4 is selected from hydrogen, optionally substituted C 3-12 -cycloalkyl, —(CH 2 ) 0-2 -(optionally substituted aryl), —(CH 2 ) 0-2 -(optionally substituted heteroaryl) and —(CH 2 ) 0-2 -(optionally substituted heterocyclyl); and
R 4 * is hydrogen.
16. The compound according to claim 1 , which is selected from the following compounds:
3-(6-(Morpholinosulfonyl)hexylamino)-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione;
6-(3,4-Dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholinoeth-oxy)hexane-1-sulfonamide;
N-Cycloheptyl-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)hexane-1-sulfonamide 6-(3,4-Dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(3-morpholinopropyl)hexane-1-sulfonamide;
N-Benzyl-N-(cyclohexylmethoxy)-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-hexane-1-sulfonamide;
N-(2-cyclohexylethyl)-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)hexane-1-sulfonamide;
N-cyclohexyl-7-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholino-ethoxy)heptanamide;
N-(2-cyclohexylethoxy)-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-(2-(2-methoxyethoxyl)ethoxy)ethyl)hexane-1-sulfonamide;
N-(2-cyclohexylethoxy)-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholinoethyl)hexane-1-sulfonamide;
N-benzyl-N-(2-cyclohexylethoxy)-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-hexane-1-sulfonamide;
N-(2-cyclohexylethoxy)-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-methylhexane-1-sulfonamide;
N-(cycloheptyloxy)-7-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)heptanamide;
N-(cycloheptyloxy)-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)hexanamide;
N-(cycloheptyloxy)-8-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)octanamide;
6-(3,4-dioxo(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(3-morpholinopropyl)-N-(pyridin-3-ylmethyl)hexane-1-sulfonamide;
N-benzyl-7-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholinoethoxy)-heptanamide;
N-benzyl-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholinoethoxy)-hexanamide;
N-benzyl-8-(3,4-dioxo-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholinoethoxy)-octanamide;
6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholinoethyl)-N-(3-morpholinoethyl)hexane-1-sulfonamide;
N-(cyclohexylmethoxy)-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholinoethyl)hexane-1-sulfonamide;
N-cycloheptyl-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholino-ethyl)hexane-1-sulfonamide;
5-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)pentyl cyclohexyloxycarbamate;
5-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)pentyl cycloheptyloxycarbamate;
5-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)pentyl 2-morpholinoethoxycarbamate;
5-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)pentyl cyclohexyloxy(isopropyl)-carbamate;
5-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)pentyl cyclohexyl(2-morpholino-ethoxyl)carbamate;
N-cycloheptyl-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-methylhexane-1-sulfonamide;
N-(cyclohexylmethoxy)l-6-(3,4-dioxo-2-(pyridin-3-ylamino)cyclobut-1-enylamino)hexane-1-sulfonamide;
6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholinoeth-oxy)-N-(pyridin-3-ylmethyl)hexane-1-sulfonamide;
3-(6-(azepan-1-sulfonyl)hexylamino)-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione;
3-(6-(morpholinosulfonyl)hexylamino)-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione;
6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-methyl-N-(morpholinoethoxy)-hexane-1-sulfonamide;
N-cyclohexyl-7-(3,4-dioxo-2-(pyridin-3-ylamino)cyclobut-1-enylamino)-N-(morpholino-ethoxy)heptanamide;
6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholinoethoxy)-N-(2-morpholinoethyl)hexane-1-sulfonamide;
1 (cyclohexoxy)-3-(5-(3,4-dioxo-(pyridin-4-ylamino)cyclobut-1-enylamino)pentyl)urea;
1-(cycloheptyloxy)-3-(5-oxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)pentyl)urea;
1-(5-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)pentyl)-3-(2-morpholinoethoxy)-urea;
1-(benzyloxy)-3-(5-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)pentyl)urea;
1-cyclohexyl-3-(5-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)pentyl)-1-(2-morphinethoxy)urea;
3-(pyridin-4-ylamino)-4-(6-(pyrrolidin-1-ylsulfonyl)hexylamino)cyclobut-3-ene-1,2-dione;
3-(6-(piperidin-1-ylsulfonyl)hexylamino)-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione;
3-(6-(4-methylpiperazin-1-ylsulfonyl)hexylamino)-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione;
N-(cyclohexylmethoxy)-5-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)pentanesulfonamide;
3-(5-(morpholinosulfonyl)pentylamino)-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione;
N-(cyclohexylmethoxy)-7-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)heptanesulfonamide;
3-(7-(morpholinosulfonyl)heptylamino)-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione;
6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-isopropyl-N-(2-morpholino-ethoxy)hexane-1-sulfonamide;
N-(5-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)pentyl)morpholine-2-carboxamide;
6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(phenylcarbamoyl)hexane-1-sulfonamide;
N-Cyclohexyl-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(3-morpholino-propy)hexane-1-sulfonamide;
N-Cyclohexyl-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholino-oxy)hexane-1-sulfonamide oxalate;
N-Cyclohexyl-7-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholino-ethoxy)heptane-1-sulfonamide;
N-Cyclohexyl-5-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholino-ethoxy)pentane-1-sulfonamide;
N-(Cyclohexylmethoxy)-6-(3,4-dioxo-2-(pyridin-4-ylmethylamino)cyclobut-1-enylamino)-N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)hexane-1-sulfonamide;
3-(5-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1 enylamino)pentyl)-1-isopropyl-1-(2-morpholinoethoxy)urea;
N-cyclopentyl-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(3-morpholino-propyl)hexane-1-sulfonamide;
6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-ethyl-N-(3-morpholinopropyl)-hexane-1-sulfonamide;
N-cyclopentyl-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholino-ethoxy)hexane-1-sulfonamide;
N-cycloheptyl-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(3-morpholino-propyl)hexane-1-sulfonamide;
N-cycloheptyl-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholino-oxy)hexane-1-sulfonamide;
N-cyclohexyl-N-(3-(dimethylamino)propyl)-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)hexane-1-sulfonamide;
N-cyclobutyl-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(3-morpholino-propyl)hexane-1-sulfonamide;
N-cyclobutyl-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholino-propyl)hexane-1-sulfonamide;
N-(Cyclohexylmethoxy)-6-(3,4-dioxo-2-(pyridin-3-ylmethylamino)cyclobut-1-enylamino)-N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)hexane-1-sulfonamide;
N-Cyclohexyl-7-(3,4-dioxo-2-(pyridin-4-ylmethylamino)cyclobut-1-enylamino)-N-(2-morpholinoethoxy)heptanamide;
N-Cyclohexyl-7-(3,4-dioxo-2-(pyridin-3-ylmethylamino)cyclobut-1-enylamino)-N-(2-morpholinoethoxyl)heptanamide;
N-cyclohexyl-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholino-ethylhexane-1-sulfonamide;
Ethyl N-cyclohex-P-(6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)hexyl)-phosphonimidate;
3-(6-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)hexylamino)-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione;
N-cyclobutyl-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholino-ethoxy)pentane-1-sulfonamide;
N-cyclobutyl-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(3-morpholino-propyl)pentane-1-sulfonamide;
N-cyclopentyl-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(3-morpholino-propyl)pentane-1-sulfonamide;
Ethyl 6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)hexyl(morpholino)phosphinate;
3-(6-(4-acetylpiperazin-1-ylsulfonyl)hexylamino)-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione;
6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-phenylhexane-1-sulfonamide;
N-(benzyloxy)-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-methylhexane-1-sulfonamide;
N-(benzyloxy)-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholino-ethyl)hexane-1-sulfonamide;
N-cyclopentyl-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholino-ethoxy)pentane-1-sulfonamide;
N-(4-chlorophenyl)-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-methylhexane-1-sulfonamide;
N-(4-chlorophenyl)-6-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholinoethyl)hexane-1-sulfonamide; and
N-(cyclohexylmethoxy)-6-(3,4-dioxo-2-(pyridine-4-ylamino)cyclobut-1-enylamino)-N-(2-fluoroethyl)hexane-1-sulfonamide.
17. A pharmaceutical composition comprising the compound according to claim 1 .
18. A method of treating a disease or condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT) in a mammal, said method comprising the step of administering to said mammal a pharmaceutically effective amount of the pharmaceutical composition according, to claim 17 wherein said disease or condition is selected from the group consisting of rheumatoid arthritis, atherosclerosis, and diabetes.